Abstract
The objective of this study was to assess the cost-effectiveness of extracorporeal photopheresis (ECP) compared with standard of care (SoC) therapy for the treatment of erythrodermic (stage T4, MO) cutaneous T-cell lymphoma (CTCL) patients, who are refractory to one or more systemic treatments. The perspective of the analysis was that of the Australian health care system.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
